v3.25.2
Investment in Securities
6 Months Ended
Jun. 30, 2025
Investment in Securities [Abstract]  
Investment in securities
7.Investment in securities

 

As of June 30, 2025, the Company’s investments consist of publicly traded equity securities and a convertible debenture. These investments are reported under ASC 321 – Investments in Equity Securities and ASC 320 – Investments – Debt Securities, as applicable. The Company has classified the investments as held for trading.

 

The following table summarizes the changes in investments for the six months ended June 30, 2025 and year ended December 31, 2024:

 

   Public
Company
Investment
   Private
Company
Investment
   Convertible
Debenture
   Total 
Balance, December 31, 2023  $
-
    
-
    
-
    
-
 
Purchases   
-
    139,084    
-
    139,084 
Balance, December 31, 2024  $
-
    139,084    
-
    139,084 
Purchases  $870,100    
-
    125,000    995,100 
Transfer   139,084    (139,084)   
-
    - 
Acquired in the sale of Skincare business   728,550    
-
    
-
    728,550 
Proceeds on sale   (1,109,921)   
-
    
-
    (1,109,921)
Interest   
-
    
-
    4,620    4,620 
Realized loss   (371,494)   
-
    
-
    (371,494)
Unrealized loss   56,305    
-
    182,594    238,899 
Balance, June 30, 2025  $312,624    
-
    312,214    624,838 

 

Equity Securities

 

The Company’s equity investments consist of publicly traded equity securities with readily determinable fair values. In accordance with ASC 321, these securities are measured at fair value, with changes in fair value recognized in profit or loss. For the six months ended June 30, 2025, the Company recognized a realized loss of $371,494 on the sale of equity securities, and an unrealized gain of $56,305 on equity securities still held at June 30, 2025.

 

Convertible Debenture

 

The Company also holds a convertible debenture, classified as a trading security under ASC 320, as it is held within a portfolio of investments and is intended to be converted into equity upon favorable market conditions. The debenture is measured at fair value, with changes in value recognized through profit or loss. For the six months ended June 30, 2025, the Company recognized interest income of $4,620 and an unrealized gain of $182,594 on the debenture.

Fair Value Measurement

 

The following table presents the Company’s financial instruments measured at fair value on a recurring basis as of June 30, 2025, in accordance with the fair value hierarchy of ASC 820: 

 

Fair Value Measurement Using:  Level 1   Level 2   Level 3   Total 
Equity securities  $312,624    
    
    312,624 
Convertible debenture   
-
    312,214    
    312,214 
Total  $312,624    312,214    
    624,838